Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Eli Lilly and Company, in collaboration with Merck Sharpe & Dohme Corp.
Scientific Title
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies